Browse EDNRA

Summary
SymbolEDNRA
Nameendothelin receptor type A
Aliases ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR; endothelin receptor subtype A; endothelin-1-specific receptor; E ......
Chromosomal Location4q31.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001569 patterning of blood vessels
GO:0001666 response to hypoxia
GO:0001701 in utero embryonic development
GO:0001763 morphogenesis of a branching structure
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006936 muscle contraction
GO:0006939 smooth muscle contraction
GO:0007190 activation of adenylate cyclase activity
GO:0007202 activation of phospholipase C activity
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007389 pattern specification process
GO:0007507 heart development
GO:0007585 respiratory gaseous exchange
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0010517 regulation of phospholipase activity
GO:0010518 positive regulation of phospholipase activity
GO:0010863 positive regulation of phospholipase C activity
GO:0014031 mesenchymal cell development
GO:0014032 neural crest cell development
GO:0014033 neural crest cell differentiation
GO:0014820 tonic smooth muscle contraction
GO:0014824 artery smooth muscle contraction
GO:0014829 vascular smooth muscle contraction
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030800 negative regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030803 negative regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030809 negative regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030815 negative regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030818 negative regulation of cAMP biosynthetic process
GO:0030819 positive regulation of cAMP biosynthetic process
GO:0031279 regulation of cyclase activity
GO:0031281 positive regulation of cyclase activity
GO:0035150 regulation of tube size
GO:0035239 tube morphogenesis
GO:0036293 response to decreased oxygen levels
GO:0042310 vasoconstriction
GO:0045761 regulation of adenylate cyclase activity
GO:0045762 positive regulation of adenylate cyclase activity
GO:0045980 negative regulation of nucleotide metabolic process
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0048483 autonomic nervous system development
GO:0048484 enteric nervous system development
GO:0048514 blood vessel morphogenesis
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048762 mesenchymal cell differentiation
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0050880 regulation of blood vessel size
GO:0051339 regulation of lyase activity
GO:0051349 positive regulation of lyase activity
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0052652 cyclic purine nucleotide metabolic process
GO:0055074 calcium ion homeostasis
GO:0060191 regulation of lipase activity
GO:0060193 positive regulation of lipase activity
GO:0060485 mesenchyme development
GO:0060562 epithelial tube morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0070482 response to oxygen levels
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072522 purine-containing compound biosynthetic process
GO:0086100 endothelin receptor signaling pathway
GO:0090066 regulation of anatomical structure size
GO:1900274 regulation of phospholipase C activity
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900372 negative regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900543 negative regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
Molecular Function GO:0001653 peptide receptor activity
GO:0004435 phosphatidylinositol phospholipase C activity
GO:0004620 phospholipase activity
GO:0004629 phospholipase C activity
GO:0004962 endothelin receptor activity
GO:0008081 phosphoric diester hydrolase activity
GO:0008528 G-protein coupled peptide receptor activity
GO:0016298 lipase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04024 cAMP signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
hsa04270 Vascular smooth muscle contraction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolEDNRA
Nameendothelin receptor type A
Aliases ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR; endothelin receptor subtype A; endothelin-1-specific receptor; E ......
Chromosomal Location4q31.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EDNRA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolEDNRA
Nameendothelin receptor type A
Aliases ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR; endothelin receptor subtype A; endothelin-1-specific receptor; E ......
Chromosomal Location4q31.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EDNRA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEDNRA
Nameendothelin receptor type A
Aliases ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR; endothelin receptor subtype A; endothelin-1-specific receptor; E ......
Chromosomal Location4q31.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EDNRA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.1610.0139
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.7920.11
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6960.42
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8980.0481
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.220.47
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4930.814
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3220.5
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2430.832
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4730.691
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8360.493
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0260.211
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.280.0583
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EDNRA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEDNRA
Nameendothelin receptor type A
Aliases ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR; endothelin receptor subtype A; endothelin-1-specific receptor; E ......
Chromosomal Location4q31.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EDNRA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEDNRA
Nameendothelin receptor type A
Aliases ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR; endothelin receptor subtype A; endothelin-1-specific receptor; E ......
Chromosomal Location4q31.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EDNRA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EDNRA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEDNRA
Nameendothelin receptor type A
Aliases ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR; endothelin receptor subtype A; endothelin-1-specific receptor; E ......
Chromosomal Location4q31.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EDNRA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEDNRA
Nameendothelin receptor type A
Aliases ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR; endothelin receptor subtype A; endothelin-1-specific receptor; E ......
Chromosomal Location4q31.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EDNRA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEDNRA
Nameendothelin receptor type A
Aliases ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR; endothelin receptor subtype A; endothelin-1-specific receptor; E ......
Chromosomal Location4q31.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EDNRA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEDNRA
Nameendothelin receptor type A
Aliases ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR; endothelin receptor subtype A; endothelin-1-specific receptor; E ......
Chromosomal Location4q31.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EDNRA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting EDNRA.
ID Name Drug Type Targets #Targets
DB00559BosentanSmall MoleculeEDNRA, EDNRB2
DB00945Acetylsalicylic acidSmall MoleculeAKR1C1, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, ......18
DB046742-HYDROXY-3,5-DIIODOBENZOIC ACIDSmall MoleculeAKR1C1, EDNRA2
DB04883DarusentanSmall MoleculeEDNRA1
DB05290SPP 301Small MoleculeEDNRA1
DB05367Actelion-1Small MoleculeEDNRA1
DB06199AtrasentanSmall MoleculeEDNRA1
DB06268SitaxentanSmall MoleculeEDNRA, EDNRB2
DB06403AmbrisentanSmall MoleculeEDNRA, EDNRB2
DB06460EnrasentanSmall MoleculeEDNRA, EDNRB2
DB06558TezosentanSmall MoleculeEDNRA, EDNRB2
DB06677ClazosentanSmall MoleculeEDNRA1
DB08932MacitentanSmall MoleculeEDNRA, EDNRB2
DB12548SparsentanSmall MoleculeAGT, EDNRA2